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Summary.-Acute leukaemias stimulated proliferative and cell-mediated cytotoxic
(CMC) responses in vitro in normal (unprimed) lymphocytes. Proliferation was
detected by increases in viable cell counts and [3H]dT incorporation in mixed
lymphocyte-leukaemia-cell cultures. CMC detected on cultured cell-line targets
(CCL) including K562 was generally much stronger than onfresh leukaemia cells, and
correlated with stimulation of [3H]dT uptake in the responding lymphocytes. Leu-
kaemias which were resistant as targets to CMC were able competitively to inhibit
CMC on K562, though not as efficiently as blocking by K562 itself. With one leukaemia,
blocking of CMC increased as the level of CMC on K562 was amplified by greater
numbers of stimulating cells in the sensitization phase. This suggests that in certain
cases blocking of effector cells byacute-leukaemia cells maydepend uponthe state of
activation ofthe effector cells. Lymphocytes from a leukaemia patient in remission,
treated with allogeneic leukaemia-cell immunotherapy and stimulated in vitro with
immunizing leukaemia cells, developed strong anti-leukaemic CMC. A non-imm-
unized patient's lymphocytes did not respond in this way, despite comparable
levels of CMC on K562 in both patients. Dual stimulation of unprimed normal
lymphocytes and remission lymphocytes with allogeneic or autologous leukae-
mias and various cell lines, amplified anti-leukaemic CMC, but did not markedly
alter CMC on CCL. These data do not formally exclude the mediation of in vitro-
stimulated anti-leukaemic CMC by NK-like cells, but suggest that such effector
cells differ qualitatively from NK-like cells detected in the absence of anti-leukaemic
CMC.
SINCE THE FIRST EVIDENCE that nor-
mal human peripheral-blood leucocytes
could manifest direct, spontaneous cell-
mediated cytotoxicity (CMC) on 51Cr-
labelled target cells (Kay & Sinkovics,
1974; Rosenberg et al., 1974) evidence has
accumulated from a large number of
studies (reviewed by Pross & Baines, 1977;
Herberman & Holden, 1978) which point
to the existence of a distinct population
of mononuclear cells with this property.
These are now generally referred to as
natural killer (NK) cells (Herberman &
Holden, 1978). Although the relationship
of NK cells to T and B lymphocytes and
12*
non-lymphoid mononuclear cells has been
the subject of intense investigation (re-
viewed by Herberman et al., 1979;
Saksela et al., 1979; Santoli & Koprowski,
1979) there is general agreement that
human NK cells do not express cell-,
surface immunoglobulin, or C3 receptors,
but do have Fc receptors (Pross & Jondal
1975; Pross et al., 1977; Nelson et al.,
West et al., 1977; Bakacs et al., 1977) and
are non-adherent to plastic surfaces and
nylon fibres (Santoli & Koprowski, 1979;
Herberman et al., 1979).
NK cells can be detected by their
capacity to lyse cultured cell-lines (CCL)G. M. TAYLOR
of malignant origin, and speculation has
thus focused upon the role that NK cells
might play in the prevention of tumour-
cell growth in vivo (Pross & Baines, 1977;
IHerberman & Holden, 1978; Santoli &
Koprowski, 1979). However, it has yet to
be shown conclusively that NK cells are
responsible for the lysis of fresh human
leukaemia cells, even though spontaneous
CMC against autologous acute leukaemias
has been reported (Herberman et al.,
1974). In this respect procedures for the
specific purification of NK cells, such as
those based upon absorption on target-
cell monolayers (Jensen et al., 1979) are
likely to be useful.
Stimulation of human lymphocytes in
mixed leucocyte cultures by a variety of
cell types leads to augmented CMC on
cultured cell lines (Callewaert et al., 1975,
1977; Jondal & Targan, 1978; Ortaldo &
Bonnard, 1977). This CMC can be dis-
tinguished in its kinetic characteristics
from allospecific T-cell cytotoxicity and
may be mediated by NK or activated NK
cells (Seeley & (Golub, 1978). Lymphocytes
from acute leukaemia patients in remis-
sion, stimulated in vitro with allogeneic
acute leukaemia cells, develop CMC to
fresh leukaemias only when patients have
been immunized in vivo with leukaemia-
cell immunotherapy (Taylor et al., 1979).
The purpose of this study was to assess
the capacity of different leukaemias to
amplify in vitro or block CMC in normal
and primed lymphocytes on leukaemia
and CCL targets as a means ofdetermining
the relationship between anti-leukaemic
CMC and CMC on cell lines.
MATERIALS AND METHODS
Preparation of lynmphocytes
Blood donors included normal individuals
and acute leukaemia patients in remission.
Remission induction and immunotherapy of
the leukaemia patients have been described
(Taylor et al., 1979). Defibrinated blood was
diluted 1:1 with Hanks' Balanced Salt Solu-
tion (HBSS) and separated on lymphocyte-
separation medium (LSM, sp. gr. 1077, Flow
Laboratories, frvine, Scotland). Lymphocytes
obtained at the LSM-plasma interface were
diluted with Eagle's medium +foetal calf
serum (MEM-FCS) and sedimented by
centrifugation. The lymphocytes were re-
suspended in MEM-FCS, washed and re-
suspended in RPMI-1640 containing 10%
heat-inactivated AB serum (1640-AB).
Cultured cell lines (CCL)
The CCI used in this study were K562, an
erythroleukaemia (Lozzio & Lozzio, 1975;
Andersson et al., 1979), CCRF-CEM and
MOLT 4 (T-cell leukaemias), Daudi (Burkitt's
lymphoma) AA-F, T51 and PRIESS (B
lymphoblastoid cells). They were cultured in
500ml glass bottles in - 100 ml of 1640-FCS
(10%) and antibiotics at 37TC in a 950o air/
500 CO2 gas mixture. Media were changed
twice weekly, and only actively growing
cells with > 9500 viability were used as
targets.
Leukaemia cells
The procurement of leukaemia cells, their
separation from peripheral blood, freezing
and storage have been described elsewhere
(Taylor et al., 1979). The cells are denoted by
their laboratory codes and are ofthe following
diagnostic types: AL-45 (AML), AL-47X
(ALL), AL-48 (AMoL), AL-49 (AMML),
AL-51 (AML), AL-E72 (AMML).
Abbreviations: AML=acute myeloblastic
leukaemia; AMoL=acute monoblastic leu-
kaemia; ALL =acute lymphoblastic leukae-
mia; AMML=acute myelomonocytic leu-
kaemia; AL=acute leukaemia.
Nylon-columnn separation
Lymphocytes were separated into nylon-
adherent and non-adherent cells by passage
through nylon columns, according to the
method ofJulius et al. (1973). Briefly, washed
nylon from a Fenwal Leucopak (Travenol
Laboratories) was packed to the lml mark
of a 5ml syringe and incubated with 5 ml of
1640-HEPES for 30 min at 37TC. One ml of
lymphocyte suspension (2-4 x 107 cells) was
added and the column incubated for 30 min
at 37TC. The non-adhering lymphocytes were
washed through with warm 1640-HEPES-
FCS and collected in a final volume of 10 ml.
They were sedimented by centrifugation and
resuspended in 1640-AB for culture.
158CMC STIMULATED BY LEUKAEMIAS
ulixed leucocyte cultures
Unfiltered or nylon-non-adherent lympho-
cytes were adjusted to 2 x 106/ml for use as
responding cells. Stimulating cells were
CCL, leukaemia cells or allogeneic lympho-
cytes, treated either with Mitomycin C (MC,
Sigma Chemical Co., Kingston-upon-Thames)
at a concentration of 50-100 ,ug/107 cells for
30 min at 37°C, or with 60 Gy from a 137CS
source. Stimulating cells were washed 3 x
after MC treatment, but not after irradiation,
and adjusted to 2 x 106/ml. Equal volumes
(2 ml) of responding and stimulating cells
were mixed in round-bottomed plastic tissue-
culture tubes (Sterilin, Teddington). The
tubes were gassed with 95%O air/500 C02,
transferred to a humidified Gas-Pak 150 jar
(Beckton-Dickinson, Wembley)andincubated
at 37°C for 6 days (day of culture=Day 0).
Replicate cultures were then harvested and
pooled, washed once in 1640-HEPES-FCS
and adjusted to cell concentrations appro-
priate for CMC assays.
Cell-mediated cytotoxicity
Taryet cells-.These included PHA-trans-
formed lymphocytes, CCL and leukaemia
cells. Normal lymphocytes (106/ml) were
transformed by incubation for 3 days with
PHA (Difco PHA-P, 10 ,ul of a 1/100 diluted
stock solution/ml culture). Leukaemia cells
and CCL were prepared as described pre-
viously (Taylor et al., 1979). All target cells
were labelled with 200 ltCi 51Cr (CJS IP,
sp. act. 1 mCi/mol., Radiochemical Centre,
Amersham) for 1 h at 20°C. The targets were
then washed once by centrifugation in 1640-
HEPES-FCS, the sedimented cells resus-
pended in 10 ml of the same medium and
reincubated for a further hour at 20°C. The
cells were then washed twice, and the con-
centration adjusted to 5 x 104/ml or 105/ml
for CMC assays.
CMC assay.-One hundred jtl of effector
cells were mixed with 100 ,ul of the appro-
priate targets in microplates with 96 round-
bottomed wells (M24ART, Sterilin). Each
effector: target combination was tested in
triplicate, at a ratio of50:1 or, for the calcula-
tion oflytic units (LU) at ratios of40, 20 and
10:1.
Blocking of CMC by "cold" targets was
performed by adding 100 ,A of cultured
lymphocytes and 50 ,ul of unlabelled target
cells (2 x 105/ml) to each microplate well. The
plates were spun at 60 q, incubated for 30
min at 37°C and 50 I,l of 5lCr-labelled K562
targets (2 x 104/ml) then added, giving a
blocker: target-cell ratio of 10:1.
CMC assays were incubated at 37°C for
6 h in a humidified Gas-Pak 150 jar, then
spun at 60 g for 5 min, and supernatanlts
harvested with a SKATRON/Titertek super-
natant harvester (FlowT Laboratories). 5ICr
in the supernatants was detected on a Wallac
DECEM GTL 300-500 gamma scintillation
counter.
Percentage cytotoxicity (0o CMC) wras cal-
culated from: E - S/T- S x 100, where E =
experimental 51Cr release in the presence of
lymphocytes, S =spontaneous 5ICr released
by target cells alone, and T =total 51Cr
released by adding 20% Triton x 100 and
freeze-thawing x 3.
Lytic units (LU) were calculated from
slopes of 00 CMC against effector:target
(E: T) ratio. One LU was the number of
effector cells needed to give 20% cytotoxicity
on K562 target cells. Results are expressed
as LU/107 effector cells.
3H-Thymidine incorporation. Mixed cell
cultures were resuspended after 6 days and
200 pi of each culture transferred to each of
4 microplate wells (M24ART). Each well was
labelled with 2 ,uCi [3H]-dT (TRK-120 sp. act.
20 mCi/mmol, Radiochemical Centre, Amer-
sham). The microplates were incubated
(as above) for 18 h and harvested on to glass-
fibre filters with a SKATRON/Titertek cell
harvester (Flow Laboratories). The filters
were dried overnight at 37°C in polypropylene
scintillation vials, then 5 ml of toluene-based
scintillation cocktail was added and [3H]-dT
uptake counted on a Beckman LS-3155T
liquid scintillation counter. The results (mean
et/min+ s.d.) are in some cases expressed as
stimulation indices, with ct/min in stimulated
lymphocytes divided by that in unstimulated
controls.
RESULTS
Stimulation ofCMC by acute leukaemnias
Previous results showed that both un-
primed and in vivo-primed remission
lymphocytes from leukaemia patients re-
ceiving immunotherapy developed CMC to
CCL after in vitro stimulation with allo-
geneic leukaemia cells (Taylor et al., 1979).
This was investigated in greater detail as
follows.
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Experiments were performed in which
unprimed normallymphocytes were stimu-
lated in vitro with allogeneic acute
leukaemia cells (from donors of AL-E72,
47X and 48) or allogeneic lymphocytes at
responder:stimulator ratios (R:S) of I: 1.
After 6 days, aliqnots of each culture were
labelled with [3H]-dT, and the remainder
tested for CMC. The results in Fig. show
the uptake of [3H]-dT by stimulated com-
pared with unstimulated lymphpd cytes,
and CMC against targets which included
autologous PHA-transformed lympho-
cytes, AL-E72 and AL-48 and the CCL's
CCRF-CEM (CEM) and K562.
No CMC was detected on autologous
lymphocytes or leukaemia 48, but was
positive on E72, CEM and K562. CMC on
the CCLs was > 40s, irrespective of the
stimulating cells and appeared to correlate
with [3H]-dT uptake.
This relationship is illustrated in Fig. 2,
where the percentage CMC on K562 target
cells by lymphocytes stimulated with
leukaemias, CCL and allogeneic lympho-
cytes is plotted against the [3H]-dT
stimulation index. The results are clus-
tered around the slope drawn between
the lowest (unstimulated) and highest
(stimulated) values for one of the lympho-
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FIG. 2. Relationship between % CMC and
[3H]-dT stimulation index induced by
leukaemias (47X, 48, E72, Ju), culturedi
cell lines (T51, AA-F and Priess) andt
allogeneic lymphocytes (D3) in lympho-
cytes from (ionors 1 (0) and 2 (0). CMC
was measured on K562 after 6 days'
culture. [3H]-dT incorporation was meas-
ured after a further 18h pulse with 2 ,uCi/
200 I1 culture.
60
cyte donors, suggesting a positive correla-
tion between 13H]-dT uptake and CMC on
K562 target cells.
In Fig. 3, the relationship between
CMC on K562, [3H]-dT uptake and cell
proliferation is shown for lymphocytes
from 4 donors (A-D) stimulated with 4
leukaemias (45, 47X, 48, 49), using a series
of R:S ratios. With the exception of
Donor B's response to AL-47X (ALL), aug-
mented CMC was paralleled by increased
cell-proliferation and [3H]-dT uptake with
increasing numbers of cells. Nevertheless,
no CMC was detected using these lympho-
cytes on homologous (i.e. stimulating)
leukaemias as targets (CMC values <100%,
data not shown). Augmentation of CMC
on K562 appeared to outpace both cell-
proliferation and [3H]-dT uptake in re-
sponse to AL-45 (A) and AL-48 (C). Donor
B's response to AL-47X was markedly de-
pressed compared with CMC in unstimu-
lated lymphocytes, which may relate to
the high level of CMC in the unstimulated
Mg
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FIG. 3. Relationship between CMC on K562 induced by leukaemias (A) 45, (B) 47X, (C) 48 and
(D) 49 (* *) and MLC (*) [3H]-dT stimulation (0 - -- 0) and viable cells/ml (O --- Q) in
cultures of normal lymphocytes stimulated at R: S ratios (1: 0, 1: 1, 1: 2 and 1: 4) with leukaemias.
MLC cultures at ratios of 1 :1.
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FIG. 4. Effect of "Cold" leukaemia 48 (O) and K562 (U) on CMC against K562 targets (P).
Lymphocytes were stimulated with leukaemia 48 or in MLC at various R:S with leukaemias
( 1: 0, 1: 1, 1: 2, 1:4) orlymphocytes (1: 1). "Cold" competitor: target cell ratio, 10: 1. Effector: target
ratios for LU calculations: 40, 20, 10:1. Maximum detectable CMC on leukaemia 48 was 10%. CMC
on K562 by competitor cells and targets alone was (1) K562: 0 7%, (2) leukaemia 48: 6%. Results
of [3H]-dT stimulation (0 - -- 0) and cell proliferation (O - -- 0) in these cultures, are shown.
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TABLE I.-Ability of leukaemias to block CMC on K562
Srimnu- R:S -
lator ratio
AL-45 1: 0
1: 2
1:4
AILC 1: 1
AL-47X 1: 0
1:1
1: 2 1
1:4
MILC 1:1
AL-48 1: 0
1: 1
1- 2
1:4
AILC 1: 1
AL-49 1: 1
1:2
1:4
IMILC 1: 1
CMC
Donor 1
0 Blocking t
SI* (LU/107) AL
1.0 55 10
7-7 100( N.D.+
6-7 200 29
4-3 500 80
1-0 166 50
1-4 37 8
13-2 105 38
6-4 133 - 40
2 7 800 N.D.
1-0 64 44
1l5 800 10
3-5 800 10
7-4 800 30
5 7 840 83
-- 62 51
133 43
200 55
133 4 13
K5
Donor 2
)yt CAMC % Blocking by
i62 SI (LU/107) AL K562
92
96
83
91
99
98
99
98
N.D.
97
80
90
88
98
98
98
97
99
1.0
6(9
6;3
3-2
1-0
0-8
1*1
1-8
7-4
1.0
2-6
5-4
6-0
5-2
62
166
285
250
25
27
20
17
4:3
55
105
250
800
250
55
55
100
35
-45
-71
51
0
30)
24
22
26
58
29
25
50
75
79
19
10
29
-17
75
80
87
100
87
98
97
96
97
98
88
90
93
98
98
98
97
94
* Stimtulation index as in Methods.
t Stimuilating cells and blocking cells identical in eaclh test. Values= % blocking
1_ (LU/107 cells witlh blockers) x 100
(LU/107 cells wiithout blockers)
I N.D.=not (lone.
lymphocytes. From additional studies with
unprimed donors, a number of factors,
including donor responsiveness, type of
stimulating cell and R:S ratio, influenced
the level ofCMC on K562, without eliciting
significant levels of CMC on most leukae-
mias.
Blocking of CMC by acute leukaemias
The lymphocytes stimulated in the
above experiments with allogeneic leu-
kaemias or with allogeneic lymphocytes
were tested for CMC on K562 targets in
the presence of unlabelled homologous
leukaemias or K562. CMC was partially
blocked by AL-48 and almost completely
blocked by K562 (Fig. 4). Indeed, blocking
byAL-48 was more effective on stimulated
than on unstimulated lymphocytes and
the extent of blocking was greater in
lymphocytes stimulated at an R: S of 1: 4
than at 1: 2. These and the results of
blocking tests with AL-44, 47X and 49, are
summarized in Table 1.
CMC stimulated in vitro by leukaemias
and allogeneic lymphocytes was to varying
degrees blocked by all leukaemias. How-
ever, in a number of tests negative block-
ing (i.e., augmented CMC on K562) was
detected in the presence of "cold" leu-
kaemia cells. Blocking was always positive
in the presence of K562.
Stimulation of CMC in primed lymphocytes
Since primed lymphocytes from patients
treated with active immunotherapy (109
X-irradiated leukaemia cells +BCG) ex-
hibit anti-leukaemic CMC following in
--vitro stimulation- (Taylor et al., 1979), a
--comparison was made with CMC on K562.
Thirteen individuals were studied, of
whom 7 were acute leukaemia patients on
immunotherapy, 2 were patients not re-
ceiving immunotherapy, and 4 were nor-
mal healthy donors. Lymphocytes from
each donor were divided into two samples,
one of which was passed through a nylon
column. and the non-adherent cells col-
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lected. Both samples were then cultured
either alone, with allogeneic lymphocytes
(MLC) as positive control, or with AL-49
leukaemia cells. CMC was assayed on auto-
logous or allogeneic PHA-transformed
lymphocytes, AL-49 and K562 targets.
For brevity the response by one patient
ptimed with immunotherapy (MM) is
compared in Fig. 5 with the response by an
unprimed patient. In all tests no CMC was
detected on autologous lymphocytes, and
with one exception CMC was positive on
allogeneic lymphocyte targets in lympho-
cytes stimulated in MLC.
Responses by the normal donors were
similar to those of patient EH in that (1)
4p
1SW
EH NONE 2
3_
1 014
MM NONE
2
3
4
PERCENT CYTOTOXICITY
N 8 8~~
MLC 2
4
MM MLC 2
3
2
EM AL 49 3 3) 4
~~MM t3, 3EI
FIa. 5. Comparison between CMC induced
by allogeneic lymphocytes (MLC) and
leukaemia 49 on lymphocytes from two
remission AML patients. EH was un-
treated, MM given weekly injections ofallo-
geneic leukaemia cells (109/wk), including
AL-49, and 106 BCG organisms. Cultures at
R:S ratios of 1:Oand 1:1. Targetswere (1)
autologous ([) and (2) allogeneic (D-1)
PHA-transformed lymphocytes (the latter
identical to MLCstimulator2), (3)leukaemia
49 (*) and (4) K562 (u). Upper histo-
gram for each target indicates CMC by
Ficoll-separated, cultured lymphocytes;
lower indicates CMC by nylon-column non-
adherent cultured lymphocytes.
no significant CMC was elicited by AL-49
targets, but increases in CMC on K562
were detected; and (2) nylon fractionation
slightly lowered the CMC generated in
response to AL-49 on K562 targets.
Of the primed patients, the results for
one (MM) shown in Fig. 5 are representa-
tive of 5 who responded to leukaemia cells
with (1) positive CMC on AL-49 and
K562, and (2) increased CMC on K562,
but decreased CMC on AL-49 in the nylon-
non-adherent fraction.
Stimulation of NVK-like CMC and anti-
leukaemic CMC
Though anti-leukaemic CMC can easily
be detected in primed lymphocytes, un-
primed lymphocytes manifest low anti-
leukaemic CMC, in spite of high levels of
NK-like CMC simultaneously detected on
CCL such as K562. CMC to autologous
leukaemias has been induced using mix-
PERCENT CYTOTOXICITY
STIMULATOR TARGET d o
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j:::::::::;;;.: ::.-:: :.--:------
r
2
MLC 3
______OR
MLC+ AL 45 4
5
6
DAUDI 3 ______OR
DAUDI + AL 45 4
5
6
2
MOLT4 3
OR 4
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FIG. 6. CMC induced in normal lympho-
cytes by leukaemia 45, alone or co-stimu-
lated with allogeneic lymrphocytes (MLC),
Daudi or MOLT-4. Targets were (1) auto-
logous (LI) and (3) allogeneic (MLC stimu-
lating, *) PHA lymphocytes, (2) leuk-
aemia 45 (Li1), (4) Daudi (E), (5) MOLT-4
(0) and (6) K562 (LI). The upper histo-
gram for each target indicates the single
stimulated culture (e.g. none, MLC, Daudi
or AIOLT-4), the lower histogram indicates
the dual-stimtulated cultture (e.g. plus
leukaemia 45).
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tures of allogeneic cells with or without
autologous leukaemias (Zarling et al.,
1976; 1978; Sondel et al., 1976; Lee &
Oliver, 1978), and it has been implied (Lee
& Oliver, 1978) that lymphocytes of B-cell
origin are necessary to induce anti-
leukaemic CMC. B-lymphloid cell-lines
also stimulate strong NK-like CMC in
vitro (Jondal & Targan, 1978). The induc-
tion of anti-leukaemic CMC in normal
allogeneic and remission autologous leu-
kaemia lymphocytes using both B and T
co-stimulating cells was investigated. In
Fig. 6 the response ofnormal lymphocytes
to AL-45 alone or admixed with Daudi
(B cells), MOLT 4 (T cells) or unrelated
allogeneic lymphocytes (MLC) is com-
pared. Targets are numbered for conveni-
ence (see legend) and the histograms
presented to compare the single or double
stimulating cell populations. Unstimulated
lymphocytes were not cytotoxic, but AL-
45 elicited modest lysis of AL-45 targets
and intermediate levels of lytic activity
on CCL (35-40%O) including Daudi, MOLT
4 and K562. Allogeneic lymphocytes
elicited lysis of AL-45 (-, 10%), but when
mixed with AL-45 enhanced NK-like lysis
of K562 (. 60%) without affecting lysis
of AL-45. Conspicuously, Daudi and AL-
45 stimulation showed marked lysis of
AL-45 (32%) compared with stimulation
by AL-45 (' 10%) or Daudi alone (<8%)
together with efficient lysis of K562
( 60%) but reduced lysis of MOLT 4
( 30%). Although Daudi induced syner-
gistic CMC on AL-45, but MOLT 4 did
not, the latter amplified CMC on the CCL
in comparison with unstimulated lympho-
cytes, and the addition of AL-45 had a
marginally additive effect. A similar
approach was used in which remission
lymphocytes from patient GR primed with
immunotherapy were stimulated with
autologous (AL-45), or allogeneic (AL-49)
leukaemia cells, alone or admixed or with
Daudi (B) or CEM (T) CCL with or
without AL-51. The results are shown in
Table II. Lysis of autologous PHA
lymphoblasts was significant ( 15%),
and CMC on autologous leukaemia cells
(AL-51) was amplified when lymphocytes
were stimulated with Daudi, CEM and
AL-49, the effect of simultaneous stimula-
tion with AL-51 being to depress the
response. CMC on AL-49 targets was
detected only in lymphocytes stimulated
with this leukaemia, whereas relatively
high lytic activity was detected on Daudi,
CEM and K562 targets in all cultures.
None of the assays detected marked dif-
ferences in NK-like CMC in cultures con-
taining CCL alone or with AL-51. AL-51
alone failed to amplify CMC on Daudi and
CEM and only slightly increased CMC on
K562. This test was repeated on Patient
GR on 3 further occasions, after further
courses of immunotherapy. None of the
stimulated lymphocytes exhibited positive
CMC on AL-5I, though CMC was detected
on AL-49 (> 25%) on Daudi, CCRF-CEM
and K562 (all > 50%). In 2 of the 3 tests,
TABLE II. Stimulation of CMC to autologous leukaemia by CCL (Patient GR)
°h CMC by GR lympphocytes on 51Cr-labelled
I~~___
Lymplhocytes
stimtulate(l witli*
Nil
AL-51 (autologotis)t
AL-49 (allogeneie)l
AL-49 + AL-51
Daudi
D)audi + Al -5I
CEM
CENI+AL-51
Auto.
L/blast,.
1-0
I ()
11-7
9-6
14-2
I 1-3
8-4
6-6
Auto.
AL-51
1-2
8-9
38-8
25-8
35-7
16-5
33-7
)4.9
* All stimulating cells irradiated at 60 Gy.
t GR acute-phase leukaemia cells.
t Immunotherapy leukaemia eells.
Allo.
AL-49
0-6
31-9
33-2
2-6
6-3
6-1
5-2
I)audi
13-3
9-6
52-0
57-6
59-2
55-0
49.9
48-3
CEM
46-2
34-4
61-2
61-2
70-6
72-0
60-9
69-3
K562
I 18
15-7
65-0
65-0
55-0
50-4
59-0
59 0
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TABLE III.-Effect of conditioned medium on CMC
C'ulture me(lilm (-
from*
A
A x B,.
A x AL-49,x
A x B, +AL-49,.
Control
% CMC on AL-49 byt
_ _ _~~~-A
A A x AL-49,X B B x AL-49,
1 1 -7 0
2 -0 3 -10 -5
-4 12 -7 24
3 9 6 26
1 15 -4 16
0/0 CAIC on K562 byt
r---~~~~-A
A A x AL-49, B B x AL-49,x
52 67 27 85
35 74 47 73
53 75 52 78
72 74 78 62
47 69 41 70
* Lymphocytes from Donor A cultured at 2 x 106 /ml for 7 days alone or withl irradiate(l lymphocytes from
Donor B or AL-49, or B + AL-49. Control medium contained no cells.
t Fresh lymphocytes from Donors A and B incubated alone or with irradiated AL-49 for 7 clays in media
conditioned as described above, then testedl for CNIC on AL-49 andI K562.
AL-51 also stimulated greater CMC on
CCL targets than was found in unstimu-
lated GR lymphocytes. On K562 this
increased from 10% in unstimulated
lymphocytes to 21% in autologous AL-51
stimulated lymphocytes. This amounted
to 160/ of the amplification of NK-like
CMC on K562 induced by allogeneic Daudi
and CCRF-CEM.
The role of "conditioned" medium
In view of the ability of allogencic
leukaemias to stimulate CMC to CCL, the
possibility that conditioning factors were
released into the culture medium wlhich
could bring about this amplification was
investigated. Lymphocytes from a normal
donor (A) were cultured alone, with X-
irradiated allogeneic lymphocytes (B)
(AL-49 or AL-49 +B) for 6 days. The cul-
tures were centrifuged to sediment the
cells, and the media removed and filtered
through 0 22 ,um Millipore filters. Fresh
lymphocytes from A and B were then
incubated with these media, alone or with
irradiated AL-49. Control medium was
fresh ] 640-AB. After 6 days in culture, the
lymphocytes were harvested and assayed
for CMC on AL-49 and K562 (Table III).
Conditioned media had a negligible effect
on CMC by unstimulated A and B on
AL-49 targets. However, medium from A
lymphocytes stimulated with B +AL-49
amplified CMC on K562. Medium from A
lymphocytes stimulated by AL-49 or
AL-49+1B elicited CMC on AL-49 targets,
but had relatively little effect on K562.
DISCUSSION
The investigations in this paper arise
from studies of the effects of immuno-
therapy in acute leukaemia patients.
Initial observations showed that lympho-
cytes from acute leukaemia patients in
remission, primed in vivo with immuno-
therapy (allogeneic leukaemias and BCCG;
Harris et al., 1978) developed strong CMC
to immunizing leukaemia cells only when
subjected to in vitro incubation with leu-
kaemia cells (Taylor et al., 1976). That
prior in vivo immunization was essential
was apparent, since normal and remission
acute leukaemic lymphocytes from non-
immunized subjects failed to develop
strong anti-leukaem-ic CMC under the
same incubation conditions. (Taylor et al.,
1976, 1979).
In this paper these investigations have
been carried fuLrther. The leukaemias
studied here were found to induce strong
CMC in unprimed, normal lymphocytes to
cultured cell lines (CCL), even though
CMC on the leukaemias as targets was
weak or negative. The amplification of
these killer cells by allogeneic leukaemias
was accompanied by [3H]-dT uptake and
cell proliferation. However, the specificity
of CMC on CCL was not related to the
type of in vitro-stimulating cell, a phe-
nomenon more in accord with effects
mediated by natural-killer (NK)-like cells
than by cytotoxic T cells.
The amplified CMC on CCL and in-
creased [3H]-dT uptake in the mixed
leucocyte cultures were positively corre-
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lated. The level of CMC on CCL could be
further amplified by increasing the num-
ber of stimulating leukaemia cells in the
mixed leucocyte cultures, without causing
an increase in CMC on the homologous
stimulating leukaemia. It has to be borne
in mind, however, that the absence ofanti-
leukaemic CMC may result from the type
ofculture conditions or from the resistance
of a particular leukaemia to cellular cyto-
lysis. Kedar et al. (1979) have looked in
more detail at these criteria, and were
able to generate anti-leukaemic CMC in
vitro in primary cultures. It is not apparent
why CMC to CCL was amplified whilst
anti-leukaemic CMC was not, in the results
presented here. These results suggest,
however, that killer cells lytic to CCL
may not be involved in the lysis of leu-
kaemia cells.
The identity of the killer cells induced
by leukaemias was not formally deter-
mined. In so far as the CMC was reactive
on all CCL tested as targets, it might be
concluded that the killer cells resemble
NK cells. It would be presumptuous to
assume thiswithout defining (i) the proper-
ties of these killer cells other than their
apparently nonspecific cytotoxic activity
on CCL and (ii) the relationship between
the induced killer cells and those in un-
stimulated peripheral-leucocyte popula-
tions. They have thus been designated
"NK-like" on the basis of their capacity
to kill CCL, which does not assume that
their progenitors are the NK cells in nor-
mal peripheral blood.
It is conceivable that the proliferative
responses induced by leukaemias relate
only indirectly to their ability to augment
NK-like CMC. Callewaert et al. (1975)
using the T-cell line HSB2, and Jondal &
Targan (1978) using the MOLT 4 T-cell
line showed their ability to amplify NK-
like CMC, whereas the proliferative stimu-
lus was very low. The CEM leukaemic
T-cell line used in this study was also
capable of augmenting NK-like CMC, as
were autologous leukaemia cells. Seeley &
Golub (1978), who demonstrated aug-
mented NK-like CMC in human MLC,
showed that it appeared before peak CTL
responses. Callewaert et al. (1978) used
BrdU to eliminate proliferating (T?) cells
in MLC, and showed that allo-specific
CML was reduced, but NK-like CMC was
not. Taken together, these results suggest
that NK-like CMC may be amplified in
mixed leucocyte cultures both by defined
(i.e., alloantigenic) and undefined stimula-
tion.
The resistance of the acute leukaemias
to NK-like CMC contrasts markedly with
the susceptibility of CCL. Most of the
CCL susceptible to NK-CMC have been
derived from leukaemias (Jondal et al.,
1978; Jondal & Targan, 1978), whereas
those derived from normal B cells by
transformation with EB virus (Jondal
et al., 1978) and mitogen-transformed
lymphocytes (Rosenberg et al., 1974;
Seeley & Golub, 1978) are largely resistant.
The capacity of leukaemias to block
CMC on K562 suggests that they may bind
NK-like effector cells without undergoing
lysis. However, one leukaemia exerted
greater blocking, the greater the amplifica-
tion ofNK-like CMC. Since thecompetitor:
target ratio was constant the increasing
efficiency of blocking may have been
related to the number or state of activa-
tion of the NK-like cells, and their
affinity for leukaemia cells. Alternatively
it could be that blocking is related to the
efficiency of leukaemia cells to absorb
endogenous conditioning factors (inter-
feron?) responsible for NK-like activity.
Thus, Trinchieri et al. (1978b) observed
that interferon-untreated cold competitor
cells inhibited interferon-amplified NK-
CMC, whereas interferon-treated com-
petitor cells did not.
The capacity of lymphocytes from only
the primed patients to develop strong
anti-leukaemic CMC contrasts with similar
levels of NK-like CMC in response to an
allogeneic leukaemia in primed and un-
primed individuals. Nylon-wool fractiona-
tion before stimulation with leukaemia
cells marginally increased NK-like CMC
in the primed patient, but slightly reduced
anti-leukaemic CMC. Both types of lytic
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activity were generated in the nylon-
non-adherent fractions, but whether this
means that NK-like CMC in primed lym-
phocytes involves the same population
as the anti-leukaemic killer cells remains
to be determined. Clearly to accommodate
this, "primed" NK-like cellswouldhave to
differ qualitatively from those stimulated
by leukaemia cellsinunprimedindividuals.
A number of studies have shown that
CMC to autologous and HLA-identical
leukaemias can be generated in lympho-
cytes stimulated with allogeneic lymphoid
cells, with or without the appropriate
leukaemia (Zarling et al., 1976, 1978;
Sondel et al., 1976; Lee & Oliver, 1978).
One interpretation ofthese findings is that
the CMC generated by allogeneic cells is
NK-like. Zarling's (1978) data using
pooled stimulating lymphocytes, without
leukaemia cells, suggests that stimulation
with a patient's leukaemia may not be
mandatory. In addition NK cells may be
stimulated by interferon to become cyto-
toxic to leukaemias (Zarling et al., 1979).
In the present study the induction of
CMC to allogeneic leukaemias by mixed-
cell stimulation did not cause the marked
increase in NK-like CMC on CCL which
might have been expected had a single
type of cytotoxic cell been responsible for
both phenomena. However, mixed-cell
stimulation might induce qualitatively
different NK-like lysis, both on CCL and
leukaemia-cells. In the case of the auto-
logous leukaemia, the most plausible ex-
planation is that a specifically antileuka-
emic cytotoxic population is amplified.
Conditioning factors released in various
mixed leucocyte cultures were able to
amplify NK-mediated lysis of K562 by
unstimulatedlymphocytes, andalsomildly
enhance the killing capacity ofleukaemia-
cell-stimulated lymphocytes on leukaemia
cells. The role ofinterferon in augmenting
NK-like cell-mediated lysis (Trinchieri
et al., 1978b; Zarling et al., 1979; Moore &
Potter, 1980) may be relevant to these
observations. Endogenous interferon is
induced in mixed lymphocyte cultures
(Gifford et al., 1971) and in mixtures of
13
lymphocytes and tumour cells within a
few hours of culture (Trinchieri et al.,
1978a). The high levels of NK-like CMC
found in lymphocyte cultures stimulated
with leukaemia cells could have been due
to either endogenous interferon or factor(s)
with similarbiologicalproperties. Factor(s)
produced by alloantigenic stimulation in
vitro (killer-cell helper factor) (Orosz &
Finke, 1978; Sopori et al., 1978) and
exogenous interferon can enhance cyto-
toxic T-cell activity (Heron et al., 1976)
and recent evidence suggests at least one
may be inseparable, biochemically, from
interferon (Simon et al., 1979).
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